Considering medication exposure in genomic association studies of cognition in psychotic disorders

References

• 1. Hill SK, Reilly JL, Harris MSH et al. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr. Res. 113(2-3), 167–175 (2009).
  MedlineGoogle Scholar
• 2. Hill SK, Reilly JL, Keefe RSE et al. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) study. Am. J. Psychiatry 170(11), 1275–1284 (2013).
  MedlineGoogle Scholar
• 3. Keefe RSE, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr. Res. 125(2-3), 161–168 (2011).
  MedlineGoogle Scholar
• 4. Keefe RSE, Harvey PD. Cognitive impairment in schizophrenia. Handb. Exp. Pharmacol. (213), 11–37 (2012).
  MedlineGoogle Scholar
• 5. Greenwood TA, Braff DL, Light GA et al. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch. Gen. Psychiatry 64(11), 1242–1250 (2007).
  MedlineGoogle Scholar
• 6. Davis OSP, Butcher LM, Docherty SJ et al. A three-stage genome-wide association study of general cognitive ability: hunting the small effects. Behav. Genet. 40(6), 759–767 (2010).
  MedlineGoogle Scholar
• 7. Visscher PM, Montgomery GW. Genome-wide association studies and human disease: from trickle to flood. JAMA 302(18), 2028–2029 (2009).
  Medline CASGoogle Scholar
• 8. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev. Neurother. 10(1), 43–57 (2010).
  Medline CASGoogle Scholar
• 9. Eum S, Hill SK, Rubin LH et al. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr. Res. 190, 129–135 (2017).
  MedlineGoogle Scholar
• 10. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J. Clin. Pharmacol. 46(12), 1481–1486 (2006).
  Medline CASGoogle Scholar
• 11. Campbell N, Boustani M, Limbil T et al. The cognitive impact of anticholinergics: a clinical review. Clin. Interv. Aging 4, 225–233 (2009).
  MedlineGoogle Scholar
• 12. Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimers. Dement. 9(4), 377–385 (2013).
  MedlineGoogle Scholar
• 13. Pasina L, Djade CD, Lucca U et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging 30(2), 103–112 (2013).
  Medline CASGoogle Scholar
• 14. Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 36(1), 52–73 (2011).
  Medline CASGoogle Scholar
• 15. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol. Psychiatry 48(5), 381–388 (2000).
  Medline CASGoogle Scholar
• 16. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am. J. Psychiatry 158(6), 918–925 (2001).
  Medline CASGoogle Scholar
• 17. Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol. Psychiatry 61(10), 1161–1170 (2007).
  Medline CASGoogle Scholar
• 18. Zavitsanou K, Katsifis A, Mattner F, Huang X-F. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29(3), 619–625 (2004).
  MedlineGoogle Scholar
• 19. Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry 139(11), 1460–1462 (1982).
  Medline CASGoogle Scholar
• 20. Strauss ME, Reynolds KS, Jayaram G, Tune LE. Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res. 3(2), 127–129 (1990).
  Medline CASGoogle Scholar
• 21. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 166(9), 1055–1062 (2009).
  MedlineGoogle Scholar
• 22. Wojtalik JA, Eack SM, Pollock BG, Keshavan MS. Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia. Psychiatry Res. 204(2-3), 61–67 (2012).
  Medline CASGoogle Scholar
• 23. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 161(1), 116–124 (2004).
  MedlineGoogle Scholar
• 24. Baitz HA, Thornton AE, Procyshyn RM et al. Antipsychotic medications: linking receptor antagonism to neuropsychological functioning in first episode psychosis. J. Int. Neuropsychol. Soc. 18(4), 717–727 (2012).
  MedlineGoogle Scholar
• 25. Ang MS, Abdul Rashid NA, Lam M et al. The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. J. Clin. Psychopharmacol. 37(6), 651–656 (2017).
  MedlineGoogle Scholar
• 26. Tsoutsoulas C, Mulsant BH, Kumar S et al. Anticholinergic burden and cognition in older patients with schizophrenia. J. Clin. Psychiatry 78(9), e1284–e1290 (2017).
  MedlineGoogle Scholar
• 27. Ballesteros A, Sánchez-Torres AM, López-Ilundain JM et al. Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis? Psychol. Med. 48(13), 2247–2256 (2018).
  MedlineGoogle Scholar
• 28. Kim S-J, Jung D, Shim J-C et al. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia. Asian J. Psychiatr. 46, 111–117 (2019).
  MedlineGoogle Scholar
• 29. Joshi YB, Thomas ML, Braff DL et al. Anticholinergic medication burden-associated cognitive impairment in schizophrenia. Am. J. Psychiatry 178(9), 838–847 (2021).
  MedlineGoogle Scholar
• 30. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging health 4(3), 311–320 (2008).
  CASGoogle Scholar
• 31. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch. Intern. Med. 168(5), 508–513 (2008).
  MedlineGoogle Scholar
• 32. Chandramouleeshwaran S, Ahsan N, Raymond R et al. Relationships between a new cultured cell-based serum anticholinergic activity assay and anticholinergic burden scales or cognitive performance in older adults. Am. J. Geriatr. Psychiatry 29(12), 1239–1252 (2021).
  MedlineGoogle Scholar
• 33. Mangoni AA, van Munster BC, Woodman RJ, de Rooij SE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am. J. Geriatr. Psychiatry 21(8), 785–793 (2013).
  MedlineGoogle Scholar
• 34. Lampela P, Lavikainen P, Garcia-Horsman JA, Bell JS, Huupponen R, Hartikainen S. Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study. Drugs Aging 30(5), 321–330 (2013).
  Medline CASGoogle Scholar
• 35. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 15, 31 (2015).
  MedlineGoogle Scholar
• 36. Khan WU, Ghazala Z, Brooks HJ et al. The impact of anticholinergic burden on functional capacity in persons with schizophrenia across the adult life span. Schizophr. Bull. 47(1), 249–257 (2021).
  MedlineGoogle Scholar
• 37. Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D. Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. Schizophr. Res. Treatment 2016, 8213165 (2016).
  MedlineGoogle Scholar
• 38. Thornton AE, Van Snellenberg JX, Sepehry AA, Honer W. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J. Psychopharmacol. 20(3), 335–346 (2006).
  Medline CASGoogle Scholar
• 39. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol. Psychiatry 55(10), 1013–1022 (2004).
  Medline CASGoogle Scholar
• 40. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25(2), 201–222 (1999).
  Medline CASGoogle Scholar
• 41. Davidson M, Galderisi S, Weiser M et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 166(6), 675–682 (2009).
  MedlineGoogle Scholar
• 42. Keefe RSE, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64(6), 633–647 (2007).
  Medline CASGoogle Scholar
• 43. Jones MT, Strassnig MT, Harvey PD. Emerging 5-HT receptor antagonists for the treatment of schizophrenia. Expert Opin. Emerg. Drugs 25(2), 189–200 (2020).
  Medline CASGoogle Scholar
• 44. de Bruin NMWJ, Kruse CG. 5-HT6 receptor antagonists: potential efficacy for the treatment of cognitive impairment in schizophrenia. Curr. Pharm. Des. 21(26), 3739–3759 (2015).
  Medline CASGoogle Scholar
• 45. Meltzer HY. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb. Exp. Pharmacol. (212), 87–124 (2012).
  MedlineGoogle Scholar
• 46. Baldez DP, Biazus TB, Rabelo-da-Ponte FD et al. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials. Neurosci. Biobehav. Rev. 126, 265–275 (2021).
  MedlineGoogle Scholar
• 47. Strauss ME, Lew MF, Coyle JT, Tune LE. Psychopharmacologic and clinical correlates of attention in chronic schizophrenia. Am. J. Psychiatry 142(4), 497–499 (1985).
  Medline CASGoogle Scholar
• 48. Sweeney JA, Keilp JG, Haas GL, Hill J, Weiden PJ. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res. 37(3), 297–308 (1991).
  Medline CASGoogle Scholar
• 49. Hori H, Noguchi H, Hashimoto R et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr. Res. 86(1-3), 138–146 (2006).
  MedlineGoogle Scholar
• 50. Elie D, Poirier M, Chianetta J, Durand M, Grégoire C, Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J. Psychopharmacol. 24(7), 1037–1044 (2010).
  Medline CASGoogle Scholar
• 51. Kontis D, Theochari E, Kleisas S et al. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(7), 1333–1341 (2010).
  Medline CASGoogle Scholar
• 52. Pickar D, Vinik J, Bartko JJ. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLOS ONE 3(9), e3150 (2008).
  MedlineGoogle Scholar
• 53. Reilly JL, Lencer R, Bishop JR, Keedy S, Sweeney JA. Pharmacological treatment effects on eye movement control. Brain Cogn. 68(3), 415–435 (2008).
  MedlineGoogle Scholar
• 54. Siepmann M, Grossmann J, Mück-Weymann M, Kirch W. Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology 168(3), 293–298 (2003).
  Medline CASGoogle Scholar
• 55. Wadsworth EJK, Moss SC, Simpson SA, Smith AP. SSRIs and cognitive performance in a working sample. Hum. Psychopharmacol. 20(8), 561–572 (2005).
  Medline CASGoogle Scholar
• 56. Nevado-Holgado AJ, Kim C-H, Winchester L, Gallacher J, Lovestone S. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open 6(11), e012177 (2016).
  MedlineGoogle Scholar
• 57. Goldberg JF, Burdick KE. Cognitive side effects of anticonvulsants. J. Clin. Psychiatry 62(Suppl. 14), 27–33 (2001).
  Medline CASGoogle Scholar
• 58. Steen NE, Aas M, Simonsen C et al. Serum concentrations of mood stabilizers are associated with memory, but not other cognitive domains in psychosis spectrum disorders; explorative analyses in a naturalistic setting. Int. J. Bipolar. Disord. 4(1), 24 (2016).
  MedlineGoogle Scholar
• 59. Savić B, Jerotić S, Ristić I et al. Long-term benzodiazepine prescription during maintenance therapy of individuals with psychosis spectrum disorders-associations with cognition and global functioning. Clin. Neuropharmacol. 44(3), 89–93 (2021).
  Medline CASGoogle Scholar
• 60. Baldwin DS, Aitchison K, Bateson A et al. Benzodiazepines: risks and benefits. A reconsideration. J. Psychopharmacol. 27(11), 967–971 (2013).
  Medline CASGoogle Scholar
• 61. Vares M, Saetre P, Strålin P, Levander S, Lindström E, Jönsson EG. Concomitant medication of psychoses in a lifetime perspective. Hum. Psychopharmacol. 26(4-5), 322–331 (2011).
  MedlineGoogle Scholar
• 62. Zhang L, Hill SK, Guo B et al. Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 113, 110464 (2022).
  Medline CASGoogle Scholar
• 63. Cools R, Robbins TW. Chemistry of the adaptive mind. Philos. Trans. A Math. Phys. Eng. Sci. 362(1825), 2871–2888 (2004).
  Medline CASGoogle Scholar
• 64. Egan MF, Goldberg TE, Kolachana BS et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98(12), 6917–6922 (2001).
  Medline CASGoogle Scholar
• 65. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav. 5(4), 311–328 (2006).
  Medline CASGoogle Scholar
• 66. Bilder RM, Volavka J, Czobor P et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol. Psychiatry 52(7), 701–707 (2002).
  Medline CASGoogle Scholar
• 67. Joober R, Gauthier J, Lal S et al. Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin card sorting test. Arch. Gen. Psychiatry 59(7), 662–663 (2002).
  MedlineGoogle Scholar
• 68. Goldberg TE, Egan MF, Gscheidle T et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 60(9), 889–896 (2003).
  Medline CASGoogle Scholar
• 69. Ho B-C, Wassink TH, O'Leary DS, Sheffield VC, Andreasen NC. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol. Psychiatry 10(3), 229, 287–298 (2005).
  Google Scholar
• 70. Tsai S-J, Hong C-J, Liao D-L, Lai I-C, Liou Y-J. Association study of a functional catechol-O-methyltransferase genetic polymorphism with age of onset, cognitive function, symptomatology and prognosis in chronic schizophrenia. Neuropsychobiology 49(4), 196–200 (2004).
  Medline CASGoogle Scholar
• 71. Nelson CLM, Amsbaugh HM, Reilly JL et al. Beneficial and adverse effects of antipsychotic medication on cognitive flexibility are related to COMT genotype in first episode psychosis. Schizophr. Res. 202, 212–216 (2018).
  MedlineGoogle Scholar
• 72. Bishop JR, Reilly JL, Harris MSH et al. Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia. Psychopharmacology 232(1), 145–154 (2015).
  Medline CASGoogle Scholar
• 73. Hochberger WC, Eskridge CLM, Bishop JR et al. Catechol-O-methyltransferase genotype differentially contributes to the flexibility and stability of cognitive sets in patients with psychotic disorders and their first-degree relatives. Schizophr. Res. 223, 236–241 (2020).
  MedlineGoogle Scholar
• 74. Barnett JH, Jones PB, Robbins TW, Müller U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin card sort test in schizophrenia and healthy controls. Mol. Psychiatry 12(5), 502–509 (2007).
  Medline CASGoogle Scholar
• 75. Poo MM. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2(1), 24–32 (2001).
  Medline CASGoogle Scholar
• 76. Egan MF, Kojima M, Callicott JH et al. The BDNF Val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2), 257–269 (2003).
  Medline CASGoogle Scholar
• 77. Tan YL, Zhou DF, Cao LY, Zou YZ, Wu GY, Zhang XY. Effect of the BDNF Val66Met genotype on episodic memory in schizophrenia. Schizophr. Res. 77(2-3), 355–356 (2005).
  MedlineGoogle Scholar
• 78. Dempster E, Toulopoulou T, McDonald C et al. Association between BDNF Val66met genotype and episodic memory. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134B(1), 73–75 (2005).
  MedlineGoogle Scholar
• 79. Notaras M, Hill R, van den Buuse M. A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review. Neurosci. Biobehav. Rev. 51, 15–30 (2015).
  Medline CASGoogle Scholar
• 80. Lu W, Zhang C, Yi Z, Li Z, Wu Z, Fang Y. Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia. J. Mol. Neurosci. 47(3), 505–510 (2012).
  MedlineGoogle Scholar
• 81. Zhang XY, Chen DC, Xiu MH et al. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum. Genet. 131(7), 1187–1195 (2012).
  Medline CASGoogle Scholar
• 82. Ho B-C, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch. Gen. Psychiatry 63(7), 731–740 (2006).
  Medline CASGoogle Scholar
• 83. Corvin A, Donohoe G, Hargreaves A, Gallagher L, Gill M. The cognitive genetics of neuropsychiatric disorders. Curr. Top. Behav. Neurosci. 12, 579–613 (2012).
  Medline CASGoogle Scholar
• 84. Davies G, Lam M, Harris SE et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat. Commun. 9(1), 2098 (2018).
  MedlineGoogle Scholar
• 85. Trampush JW, Yang MLZ, Yu J et al. GWAS meta-analysis reveals novel loci and genetic correlates for general cognitive function: a report from the COGENT consortium. Mol. Psychiatry 22(3), 336–345 (2017).
  Medline CASGoogle Scholar
• 86. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510), 421–427 (2014).
  MedlineGoogle Scholar
• 87. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. Genet. 43(10), 977–983 (2011).
  MedlineGoogle Scholar
• 88. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43(10), 969–976 (2011).
  MedlineGoogle Scholar
• 89. Nakahara S, Medland S, Turner JA et al. Polygenic risk score, genome-wide association, and gene set analyses of cognitive domain deficits in schizophrenia. Schizophr. Res. 201, 393–399 (2018).
  MedlineGoogle Scholar
• 90. Harvey PD, Sun N, Bigdeli TB et al. Genome-wide association study of cognitive performance in U.S. veterans with schizophrenia or bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 183(3), 181–194 (2020).
  MedlineGoogle Scholar
• 91. Eum S, Hill SK, Alliey-Rodriguez N et al. Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. Neuropsychopharmacology 46(10), 1802–1810 (2021).
  Medline CASGoogle Scholar
• 92. Lencz T, Knowles E, Davies G et al. Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: a report from the Cognitive Genomics consorTium (COGENT). Mol. Psychiatry 19(2), 168–174 (2014).
  Medline CASGoogle Scholar
• 93. Benca CE, Derringer JL, Corley RP et al. Predicting cognitive executive functioning with polygenic risk scores for psychiatric disorders. Behav. Genet. 47(1), 11–24 (2017).
  MedlineGoogle Scholar
• 94. Shafee R, Nanda P, Padmanabhan JL et al. Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. Transl. Psychiatry 8(1), 78 (2018).
  MedlineGoogle Scholar
• 95. Richards AL, Pardiñas AF, Frizzati A et al. The relationship between polygenic risk scores and cognition in schizophrenia. Schizophr. Bull. 46(2), 336–344 (2020).
  MedlineGoogle Scholar
• 96. Mallet J, Le Strat Y, Dubertret C, Gorwood P. Polygenic risk scores shed light on the relationship between schizophrenia and cognitive functioning: review and meta-analysis. J. Clin. Med. Res. 9(2), 341 (2020).
  Google Scholar
• 97. Srivastava A, Dada O, Qian J et al. Epigenetics of schizophrenia. Psychiatry Res. 305, 114218 (2021).
  Medline CASGoogle Scholar
• 98. Wu JQ, Green MJ, Gardiner EJ et al. Altered neural signaling and immune pathways in peripheral blood mononuclear cells of schizophrenia patients with cognitive impairment: a transcriptome analysis. Brain Behav. Immun. 53, 194–206 (2016).
  Medline CASGoogle Scholar
• 99. Gómez Ravetti M, Rosso OA, Berretta R, Moscato P. Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. PLOS ONE 5(4), e10153 (2010).
  MedlineGoogle Scholar
• 100. Luo C, Pi X, Hu N et al. Subtypes of schizophrenia identified by multi-omic measures associated with dysregulated immune function. Mol. Psychiatry 26(11), 6926–6936 (2021).
  Medline CASGoogle Scholar
• 101. Penadés R, García-Rizo C, Bioque M et al. The search for new biomarkers for cognition in schizophrenia. Schizophr. Res. Cogn. 2(4), 172–178 (2015).
  MedlineGoogle Scholar
• 102. Bishop JR, Zhang L, Lizano P. Inflammation subtypes and translating inflammation-related genetic findings in schizophrenia and related psychoses: a perspective on pathways for treatment stratification and novel therapies. Harv. Rev. Psychiatry 30(1), 59–70 (2022).
  MedlineGoogle Scholar
• 103. de Jong LM, Jiskoot W, Swen JJ, Manson ML. Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics. Genes 11(12), 1509 (2020).
  CASGoogle Scholar